CRISPR-Cas gene editing holds substantial promise in many biomedical disciplines and basic research. Due to the important functional implications of non-histone chromosomal protein HMG-14 (HMGN1) in regulating chromatin structure and tumor immunity, we performed gene knockout of HMGN1 by CRISPR in cancer cells and studied the following proteomic regulation events. In particular, we utilized DIA mass spectrometry (DIA-MS) and reproducibly measured more than 6200 proteins (protein-FDR 1%) and more than 82,000 peptide precursors in the single MS shots of two hours. HMGN1 protein deletion was confidently verified by DIA-MS in all of the clone-and dish-replicates following CRISPR. Statistical analysis revealed 147 proteins changed their expressions significantly after HMGN1 knockout. Functional annotation and enrichment analysis indicate the deletion of HMGN1 induces the histone inactivation, various stress pathways, remodeling of extracellular proteomes, cell proliferation, as well as immune regulation processes such as complement and coagulation cascade and interferon alpha/ gamma response in cancer cells. These results shed new lights on the cellular functions of HMGN1. We suggest that DIA-MS can be reliably used as a rapid, robust, and cost-effective proteomicscreening tool to assess the outcome of the CRISPR experiments.
Introduction 1
The clustered regularly interspaced short palindromic repeat (CRISPR) genome-editing system 2 was demonstrated to be a revolutionary tool in many biological and biomedical fields, including 3 studying gene functions, creating new cell and animal models, developing therapeutic agents, 4 and potentially to treat diseases. CRISPR-Cas9 was adapted from a naturally occurring genome 5 editing system in prokaryotic organisms that provides a form of acquired immunity [1] . In this 6 system, CRISPR sequences are DNA fragments from viruses that have previously infected the 7 prokaryote and are used to detect and destroy DNA from similar viruses during subsequent 8 infections, whereas Cas9 (or "CRISPR-associated 9") is an enzyme that cuts foreign DNA. 9
Usually, the Cas9 nuclease (or other enzymes) can be delivered with a synthetic guide RNA 10 (gRNA) into a cell so that the cell's genome can be cut at a desired location [2-6]. Following 11 DNA cleavage, researchers can use the eukaryotic cell's own repair systems to either fuse broken 12 chromosomal ends together via non-homologous end joining (NHEJ) or, in the presence of donor 13 DNA, introduce exogenous sequence via homology-directed repair (HDR), for the purpose of 14 gene knockout or knock in respectively [2] [3] [4] [5] . 15
16
A growing number of applications of CRISPR-Cas9 require a better understanding, 17 characterization, and management of CRISPR efficacy and off-target effects. Many prediction 18 tools and experimental approaches have been developed for these aims [7-10]. For example, 19
Cas9 nickase activity was used to significantly reduce off-target activity and the application of 20 paired guide RNAs (gRNAs) was shown to increase the efficiency of gene knockouts [11, 12] . 21
Currently, the successful implementation of CRISPR experiment for a target gene or gene set is 22 routinely validated by PCR using primers flanking the deleted region at the DNA level or by 23 western blotting of the protein targets at the protein level. The next generation sequencing (NGS) 24 techniques using e.g., amplicon-based kits have been successfully applied for screening 25 CRISPR-Cas9 induced mutations, efficacy, and both on-target and off-target effects [13] [14] [15] [16] . 26
27
Due to the limitations of antibody such as cross-reactivity, the mass spectrometry (MS) based 28 methods such as targeted proteomics [17, 18] have been widely adopted to detect and quantify 29 proteins of interest. Over the last decade, the proteome has become precisely measurable. The 30 acute state of the proteome-the proteotype-is a useful indicator of the cellular state and 31 important for studying disease phenotype, development, pharmacological responses, and many 1 other aspects in life science research [19, 20] . The last five years have witnessed significant 2 technological improvements in MS-based proteomics especially in proteome coverage and 3 measurement reproducibility of large sample cohorts. Particularly, data-independent acquisition 4 (DIA) methods, such as SWATH mass spectrometry (SWATH-MS) combined with targeted data 5 extraction has achieved unprecedented reproducibility, which are capable of generating 6 quantitative matrices for thousands of proteins measured across multiple samples [20] [21] [22] . 7
Recently, SWATH-MS was proven to be reproducible in a cross-lab study for >4000 proteins 8 quantified in mammalian cells [23] . Moreover, the statistical strategies controlling the quality of 9 protein identification and quantification in large-scale DIA-MS have matured [24, 25] . Because 10 proteins catalyze and control directly most biological processes, and because proteotype 11 characterization essentially bridges the genotypic variation and phenotype diversity, we propose 12 that a sensitive, reproducible, robust, and rapid proteomic measurement enabled by e.g., DIA-MS 13 would provide a general and powerful alternative approach to assess the outcome of a CRISPR 14 experiment, to not only verify the successful knockout of the target gene (and its protein 15 expression), but also to profile perturbed signaling pathways and quantitative phenotypes. 16
17
Herein, we focused on an example of a human protein, non-histone chromosomal protein HMG-18 14 (High Mobility Group Nucleosome Binding Domain 1, or HMGN1). Others and we have 19 previously observed the HMGN1 mRNA and protein overexpression in Down Syndrome (DS, 20 trisomy 21), which supports the hypothesis that HMGN1 could increase the chromatin 21 accessibility and cause transcriptional dysregulation [26, 27] . Based on previous literatures, 22
HMGN1 is associated to two major processes, transcriptional regulation and tumor immunity 23
[28-36]. Despite of the emerging importance of HMGN1, there are currently no proteomic data 24 sets available to understand the proteotype induced by its exclusive dosage imbalance in cells. In 25 the present study we therefore analyzed the HMGN1 knockout cancer cells by DIA-MS to 26 further understand the functional roles of HMGN1. 27
28

Results
29
To specifically knock out HMGN1 by CRISPR, we transfected the human T-REx-HeLa CCL2 30 cells with two gRNAs that target the second and third exon of HMGN1, respectively. Single 31 cells with positive GFP signal indicating Cas9 and gRNA expression were then sorted and 1 expanded. To investigate the proteomic variation between these cell clones, three of them 2 (named Clone A, B, and C hereafter) were verified by western blot to be negative with HMGN1 3 antibody staining, as compared to the wildtype control cells (Figure 1, left panel) , and included 4 in the study as clone-replicates. For each of A, B, C clones and the control, three independent 5 cell cultures were included as dish-replicates. These 12 samples were randomized, processed, 6
and measured by a two-hour DIA-MS on Orbitrap Lumos. Quantification was preformed based 7 on high-resolute fragment signals (MS2 resolution, 30,000), followed by bioinformatic analysis 8 (Figure 1) . 9
10
To analyse the DIA-MS data, we used both spectrum-centric [37] (named directDIA in 11
Spectronaut, a method extracting pseudo-spectrum directly from DIA data without the need of 12 an assay library [38, 39] ) and peptide-centric (based on SWATH assay library which contains 13 mass spectrometric assays for 10,000 human proteins [40], named panHuman hereafter) 14 approaches. Both approaches achieved substantial sensitivity when both peptide-and protein-15 FDR were strictly controlled at 1% (Figure 2 A-B) [25]. On average, directDIA identified and 16 quantified 5,465 ± 7 Swiss-Prot proteins, assigned from 61,476 ± 430 unique peptides (~82,840 17 ± 685 peptide precursors) in the 12 samples, whereas panHuman library detected 5625 ± 27 18 proteins corresponding to 57,920 ± 1,601 unique peptides (~68,338 ± 2,092 peptide precursors). 19
As expected, the majority of the proteins identified (i.e., 4,949 proteins) were shared between 20 directDIA and panHuman ( Figure 2C) . Interestingly, despite directDIA quantified 2.83% less 21 proteins, this library-free approach profiled 6.14% more peptides than panHuman library based 22
analysis. This could be partially explained by the fact that the panHuman library was originally 23 derived from TripleTOF platform [40], but still indicates the decent proteomic recovery, 24 essentially at the peptide level, achieved by directDIA. Impressively, directDIA reaches 98.9% 25 of data completeness in measuring all the precursors (Supplementary Figure 1) . Taken 26 together, we quantified 6,206 proteins in the combined results from the single measurements of 27 two hours, which represents 50-60% of the total proteome expressed in a cancer cell line under a 28
given condition [41] . 29
30
We next focused on analyzing the quantitative reproducibility and variation in both clone-and 1 dish-replicates. Firstly, we found that 5487, 5277, 4361, and 5501 proteins of Control, Clone A, 2 B, and C were quantified with a CV<20% in the three dish-replicates. The sample-to-sample 3 Pearson correlations were fairly high throughout the whole experiment ( Figure 2D) , with e.g., 4 average R=0.982 achieved between dish-replicates in Controls across five orders of magnitude of 5 absolute DIA MS2 intensity (see Supplementary Figure 2 for an example). Secondly, we 6 performed both hierarchical clustering analysis (HCA) and principal component analysis (PCA) 7 on the relative quantification results (Figure 2 E-F) . In both plots, we found the three dish-8 replicates of Control and Clone C could emerge as individual clusters whereas Clone A and B 9 dish-replicates were not separated from each other. The fact that Clone C showed deviation from 10 to A and B could suggest a bigger clonal effect in C that was successfully revealed by DIA-MS 11 ( Figure 2F ). In the meanwhile, Clone C has similar growth and proliferation rate to A and B 12 ( Supplementary Figure 3) . Consistent to PCA result, the average CV for Clone B dish-13
replicates was 17.4%, which was higher than that of other clones (i.e, 11.41%, 13.21%, and 14 10.13% for Control, Clone A and C respectively, Supplementary Figure 4 ), suggesting a bigger 15 dish-variation in B. Finally, all the 12 samples had an average CV of 21.56%, higher than that of 16 each clones. Also, PCA plot indicates Control samples were separated from all knockout samples 17 using the first principal component, suggesting the proteomic variation due to HMGN1 depletion 18 was successfully captured in our whole data set. Overall, DIA-MS yielded excellent 19 quantification reproducibility, providing an opportunity to faithfully reveal the de facto dish-and 20 clone-variations, and to reveal HMGN1 dosage associated proteotype changes. 21
22
To uncover differentially expressed proteins between control and knockout clones, we performed 23 statistical analysis visualized by volcano plots (Figure 3) . A total of 162, 123, and 297 proteins 24 were filtered as significantly regulated in Control vs. A, Control vs. B, and Control vs. C 25 comparisons, by using BH adjusted P value <0.05 and fold-change >2 as the criteria. 26
Remarkably, HMGN1 was identified by six unique peptides and indeed was the protein that 27 showed the largest fold-change in all of the three comparisons, with 83.42-, 67.14-, and 62.63-28 folds decreased from control to a quasi-noise level after CRISPR deletion. Of note, even in 29 control samples, the HMGN1 protein intensity ranks below No. 3100, indicating that a less 30 sensitive MS method quantifying e.g., ~3000 proteins will likely to fail in the precise 1 quantification of HMGN1. processes were disturbed or remodeled. Many proteins annotated in "Negative regulation of cell 28 proliferation" were found to be downregulated after HMGN1 deletion (Figure 5A) , which is 29 consistent to the mild but significant increase of cell proliferation observed in knockouts 30 Figure 3) . In agreement to the above BPs, cellular components (CC) such as 31 Extracellular exosome (GO:0070062, P=4.79E-04), Integral component of plasma membrane 1 (GO:0005887, P=0.0050), and Clathrin-coated vesicle (GO:0030136, P=0.0022) associated 2 proteins were differentially regulated. Two KEGG pathways, Complement and coagulation 3 cascades (P=5.72E-4) and ECM-receptor interaction (P=0.0343), were also enriched in the 147-4 protein list, reinforcing the newly discovered role of HMGN1 in immune response [33] [34] [35] [36] . 5 6
(Supplementary
To extend functional analysis to all the quantified proteins in a threshold-free manner, we 7 applied gene set enrichment analysis (GSEA) in all HMGN1 deleted cells compared to wildtype 8 controls. GSEA uncovered many biological regulations (Figure 5B , FDR q-values all below 9 0.05). In control samples, we found that the Peroxisome, Ribosome and Cholesterol biosynthesis 10 functions were upregulated, suggesting these functions are impaired when HMGN1 is removed. 11
In comparison, many more gene sets were enriched in knockout phenotypes, which could be 12 abundant member, HMGN1 belongs to HMGNs, a family of proteins which binds specifically to 3 the nucleosome core particle and reduces the compaction of the chromatin fiber [28] . HMGN1 4 has been discovered to modulate Histone H3 phosphorylation [28] and to remodel the chromatin 5 during embryogenesis [43] . In this context, this protein was found to preferentially localize to 6 DNase I hypersensitive sites, promoters, functional enhancers, and transcription factor binding 7 sites [30] and has a variant-specific and tissue-specific effect on global transcription [31, 32] . 8
Consistent to this major role of HMGN1 in regulating gene expression and DNA repair in 9 mammalians [42], we found that those genes marked by H3K27me3 in reprogrammed iPS cells 10 were enriched in knockout phenotypes using our proteomic data [44] . Even more interestingly, 11 the same gene set was found to be enriched in wildtype cells when compared to HMGN1 12 overexpressed B cell progenitors, according to a recent transcriptome analysis [27] . Taking these 13 results together, we can deduce that HMGN1 dosage, whether of overexpression, wildtype, and 14 depletion, has a linear relationship with histone activity in regulating the overall gene expression. 15 16
Secondly, in previous reports, the Hmgn1 −/− mice were found to have reduced fertility, higher 17 sensitivity to UV irradiation [29] and earlier signs of N-Nitrosodiethylamine-Induced liver 18 tumorigenesis than their wildtype littermates [45] . Loss of HMGN variants affects the expression 19 of stress-responsive genes in mouse embryonic fibroblasts (MEFs) [46] . We also found those 20 stress pathways including hypoxia and apoptosis are induced after HMGN1 knockout, potentially 21 explaining the vulnerability phenotypes discovered in Hmgn1 −/− mice. 22 23
Thirdly, the interaction of HMGN1 with chromatin was previously found to down-regulate the 24 expression of N-cadherin, a transmembrane protein mediating cell-cell adhesion [47] . Notably, 25
we detected significant proteomic changes (both up-and down-regulations) in the extracellular 26 exosome and plasma membrane sub-proteomes, which might suggest that the "outside" proteome 27 was already heavily rewired as a new state of HMGN1 deletion in the tested cell line. Further 28 studies are therefore needed to delineate the relationship between HMGN1 downregulation and 29 extracellular protein changes. 30 31
Last but not the least, HMGN1 recently was re-discovered to play an important role in immune 32 response. It was identified as an alarmin, a group of mediators capable of promoting the 33 recruitment and activation of antigen-presenting cells (APCs), including dendritic cells (DCs), 1 that can potentially alert host defense against danger signals. Yang et al reported that 2 extracellular HMGN1 acts as a novel alarmin that binds TLR4 and induces antigen-specific Th1 3 immune responses [33] and could be a potent immunoadjuvant by supporting T cell-mediated 4 antitumor immunity [34, 35] . Recently a curative therapeutic vaccination regimen dubbed 5 'TheraVac' consisting of HMGN1 and resiquimod plus a checkpoint inhibitor was developed 6
with the potential to eliminate various large tumors and induce tumor-specific immunity [36] . 7
Our proteomic profiling is promising in this regard, because complement and coagulation 8 cascades and interferon alpha or gamma responses were found to be significantly induced upon 9 HMGN1 deletion, and therefore provides additional insights of HMGN1's role in immunity. 10
11
The specific clone-and dish-effects we observed could be derived from possible CRISPR off-12 target effects, the real-time cell culturing difference, and/or experimental variations. There was 13 no apparent cell proliferation difference between knockout clones. It is conceivable that 14 proteotype provides closer scrutiny on phenotypes than mRNA profiling. Therefore, for a 15 proteomic measurement on CRISPR effect, we recommend multiple clone-and dish-replicates 16 to be included in the experiment to fully capture the proteotypic variations. 17
18
In summary, we applied a powerful DIA-MS measurement featuring decent sensitivity (>6200 19 proteins profiled), high reproducibility (R>0.98 between dish-replicates), high quantitative 20 accuracy (for both absolute and relative scale quantification), cost-effectiveness (label-free 21 quantification), and high sample throughput (2 hours per single measurement) in analyzing the 22 cellular proteome after HMGN1 CRISPR deletion. Both the targeted protein (i.e., HMGN1) and 23 the differential proteome closely associated to HMGN1 deletion were rapidly profiled. Our BioTek). 16
17
CRISPR/Cas9-mediated gene knockout 18
CRISPR guideRNAs were designed based on their specificity score retrieved from the Optimized 19 CRISPR Design web tool (http:crispr.mit.edu). Annealed DNA oligonucleotides containing the 20 target sequence were cloned into the hSpCas9 plasmid (pX458, Addgene) using BbsI restriction 21 sites. T-REx-HeLa cells were transfected with two hspCas9 constructs encoding gRNAs that 22 target the second and third exon of the target gene HMGN1, respectively. The cell culture 23 medium was replaced 4 hours after transfection and cells were recovered for 72 hours. For FACS 24 sorting 1x10e6 cells were gently detached from the tissue culture plate with 0.25% trypsin-25 EDTA (Gibco) and resuspended in PBS containing 1% FBS. GFP-positive cells were isolated by 26
FACS (BD Facs Aria IIIu sorter) and single cells were sorted into each well of a 96-well plate. 27
Cell clones were expanded for three weeks and then screened for deletion events by western-28
blotting. Below lists the information of gRNA target sequences and oligonucleotides. 
Cell lysis and in-solution digestion 20
The protein extraction and digestion were preformed as previously described [23] . Briefly, cell 21 pellets were suspended in 10M urea lysis buffer and complete protease inhibitor cocktail 22 (Roche), ultrasonically lysed at 4°C for 2 minutes by two rounds using a VialTweeter device 23 (Hielscher-Ultrasound Technology). The mixtures were centrifuged at 18,000 g for 1 hour to 24 remove the insoluble material. The supernatant protein amount was quantified by Bio-Rad 25 protein assay. Protein samples were reduced by 10mM Tris-(2-carboxyethyl)-phosphine for 1 26 hour at 37°C and 20 mM iodoacetamide in the dark for 45 minutes at room temperature. All the 27 samples were further diluted by 1:6 (v/v) with 100 mM NH 4 HCO 3 and were digested with 28 sequencing-grade porcine trypsin (Promega) at a protease/protein ratio of 1:25 overnight at 37°C. 29
The amount of the purified peptides was determined using Nanodrop ND-1000 (Thermo 30 Scientific) and 1.5 µg peptides were injected in each LC-MS run. 31 1
DIA mass spectrometry 2
The peptide separation was performed on EASY-nLC 1200 systems (Thermo Scientific) using a 3 self-packed analytical PicoFrit column (New Objective) (75 µm x 60 cm length). This 50 cm 4 column was packed with ReproSil-Pur 120A C18-Q 1.9 µm (Dr. Maisch GmbH). An LC method 5 of 2 hours was used (Buffer A: 0.1% formic acid, buffer B: 80% acetonitrile containing 0.1% 6 formic acid). Briefly, a 5% to 37% Buffer B gradient of 109-min was conducted with the flow 7 rate of 300 nl/min at 60 o C in a column oven (PRSO-V1, Sonation GmbH). The additional SWATH-MS measurements were performed as previously published [26] . 19 20
DIA data extraction and analysis 21
The DIA runs were analysed with Spectronaut Pulsar version 12.0 (Biognosys AG, Switzerland) 22
[38, 48]. In the directDIA approach, DIA runs were directly searched against Swiss-Prot protein 23 database (March 2018, 20,258 entries) with following settings: full tryptic allowing two missed 24 cleavages, set carbamidomethylation as a fixed modification on all cysteines, set oxidation of 25 methionines, protein N-terminal acetylation as dynamic modifications. Both precursor and 26 protein FDR were controlled at 1%. As for quantification, interference correction function was 27 enabled, and top 3 peptide precursors were summed for protein quantification. Data filtering was 28 done with Qvalue sparse in this 12-sample experiment. In panHuman approach, the published set 29 of mass spectrometric assays for 10,000 human proteins was downloaded [40] and the protein 30 quantitative results were summarized in the same way as directDIA. In both approaches, all the 31 other parameters in Spectronaut are kept as default unless mentioned. To combine directDIA and 1 panHuman results, the protein quantification results of those only acquired by panHuman library 2 (but not by directDIA) were simply appended into the directDIA results. used to infer the degree to which a given gene set is overrepresented at the upper or lower ends 16 of a ranked list of genes by at an estimated probability (i.e., FDR-q value). Briefly, a running-17 sum statistic is generated from the ranked list of genes, with the magnitude of the increment 18 depending on the correlation of the gene with the phenotype (control and HMGN1 deletion). 19 20 21 Acknowledgement
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